Maiwei Biotech said the FDA has formally authorized its clinical trial application for injectable 6MW5311 for hematologic malignancies, including chronic myelomonocytic leukemia (CMML) and multiple myeloma.

2026-06-12

Maiwei Biotech said the FDA has formally authorized its clinical trial application for injectable 6MW5311 for hematologic malignancies, including chronic myelomonocytic leukemia (CMML) and multiple myeloma.